E Fund Management Co., Ltd. Akebia Therapeutics, Inc. Transaction History
E Fund Management Co., Ltd.
- $2.06 Billion
- Q2 2025
A detailed history of E Fund Management Co., Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 28,273 shares of AKBA stock, worth $48,064. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,273
Previous 19,311
46.41%
Holding current value
$48,064
Previous $37,000
175.68%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AKBA
# of Institutions
189Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...